keyword
MENU ▼
Read by QxMD icon Read
search

Vaccination of multiple sclerosis patients

keyword
https://www.readbyqxmd.com/read/29761344/beyond-the-magic-bullet-current-progress-of-therapeutic-vaccination-in-multiple-sclerosis
#1
Barbara Willekens, Nathalie Cools
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS) characterized by neuroinflammation, neurodegeneration and impaired repair mechanisms that lead to neurological disability. The crux of MS is the patient's own immune cells attacking self-antigens in the CNS, namely the myelin sheath that protects nerve cells of the brain and spinal cord. Restoring antigen-specific tolerance via therapeutic vaccination is an innovative and exciting approach in MS therapy. Indeed, leveraging the body's attempt to prevent autoimmunity, i...
May 14, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29706295/recent-advances-in-the-development-of-vaccines-for-chronic-inflammatory-autoimmune-diseases
#2
REVIEW
Naru Zhang, Kutty Selva Nandakumar
Chronic inflammatory autoimmune diseases leading to target tissue destruction and disability are not only causing increase in patients' suffering but also contribute to huge economic burden for the society. General increase in life expectancy and high prevalence of these diseases both in elderly and younger population emphasize the importance of developing safe and effective vaccines. In this review, at first the possible mechanisms and risk factors associated with chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE) and type 1 diabetes (T1D) are discussed...
April 26, 2018: Vaccine
https://www.readbyqxmd.com/read/29554001/visual-outcomes-and-clinical-manifestations-of-pediatric-optic-neuritis-in-indian-population-an-institutional-study
#3
Selvakumar Ambika, Krishnakumar Padmalakshmi, Viswanathan Venkatraman, Olma V Noronha
BACKGROUND: Optic neuritis in children is an uncommon disorder which usually occurs after a viral illness or vaccination and, less frequently, occurs as a manifestation of a demyelinating disorder. Pediatric optic neuritis usually is bilateral and presents with optic disc edema, recovers rapidly with steroid therapy, and generally has low conversion rate to multiple sclerosis or neuromyelitis optica spectrum disorder. We report the clinical features and treatment outcomes of pediatric optic neuritis in Indian population, for which little data are available...
March 16, 2018: Journal of Neuro-ophthalmology: the Official Journal of the North American Neuro-Ophthalmology Society
https://www.readbyqxmd.com/read/29526320/optic-neuritis-in-paediatric-patients-experience-over-27-years-and-a-management-protocol
#4
L Monge Galindo, A L Martínez de Morentín, V Pueyo Royo, J P García Iñiguez, S Sánchez Marco, J López-Pisón, J L Peña-Segura
INTRODUCTION AND OBJECTIVE: In this article, we present our experience on optic neuritis (ON) and provide a diagnostic/therapeutic protocol, intended to rule out other aetiologies (particularly infection), and a fact sheet for parents. MATERIAL AND METHODS: We conducted a descriptive, retrospective study of patients with ON over a 27-year period (1990-2017). A review of the available scientific evidence was performed in order to draft the protocol and fact sheet...
March 8, 2018: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/29404651/-multiple-sclerosis-and-hepatitis-b-vaccination-what-does-the-verdict-of-the-european-court-of-justice-on-liability-after-vaccination-mean
#5
REVIEW
M Löbermann, B Handorn, A Winkelmann, E C Reisinger, H P Hartung, U K Zettl
In June 2017 the European Court of Justice (ECJ) issued a verdict on the legal assessment of the association between hepatitis B immunization and the subsequent manifestation of multiple sclerosis (MS). This led to a high level of insecurity in the medical field as well as the normal population, especially in MS patients. The aim of this article is to briefly present the evidence-based medical facts and in particular to clearly highlight the legal aspects of the abovenamed ECJ verdict.
February 5, 2018: Der Nervenarzt
https://www.readbyqxmd.com/read/29205701/antibody-response-to-seasonal-influenza-vaccination-in-patients-with-multiple-sclerosis-receiving-immunomodulatory-therapy
#6
H K Olberg, G E Eide, R J Cox, Å Jul-Larsen, S L Lartey, C A Vedeler, K-M Myhr
BACKGROUND AND PURPOSE: We have previously shown that patients with multiple sclerosis receiving immunomodulatory treatment have reduced seroprotection rates after influenza immunization. The aim of this study was to further investigate the influence of immunomodulatory therapies on the antibody response and seroprotection rates in patients immunized with seasonal influenza vaccine in 2012/2013 compared with healthy controls. METHODS: Ninety patients receiving fingolimod, glatiramer acetate, interferon beta-1a/1b, natalizumab or no therapy were compared with 62 healthy controls...
March 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29068486/vaccines-and-multiple-sclerosis
#7
REVIEW
J L Frederiksen, M Topsøe Mailand
An association between certain vaccinations and onset or relapse of multiple sclerosis (MS) has been debated. Based on PubMed, we made a thorough literature review and included all relevant studies, 51 on MS and 15 on optic neuritis (ON). Case studies were excluded. With the exception of a live vaccine against yellow fever, vaccinations appear safe in untreated patients with MS and ON. However, most studies were underpowered, and small risks cannot be excluded. One study of BCG vaccination after the first demyelinating event showed even a reduced risk of developing MS...
November 2017: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/28941623/post-licensure-safety-surveillance-study-of-routine-use-of-quadrivalent-meningococcal-diphtheria-toxoid-conjugate-vaccine
#8
J Hansen, L Zhang, N P Klein, C A Robertson, M D Decker, D P Greenberg, E Bassily, R Baxter
BACKGROUND: Menactra® vaccine (MenACWY-D) was licensed in the United States in 2005 for persons 11-55years of age. The aim of this study was to assess the safety of MenACWY-D administered as part of routine clinical care to patients at Kaiser Permanente Northern California (KPNC). METHODS: This was an observational, retrospective study that included all KPNC members who received MenACWY-D during the study period. We monitored all vaccine recipients for non-elective hospitalizations, emergency department visits, and selected outcomes captured in the clinic setting (Bell's palsy, seizures, neuritis, Guillain-Barré syndrome, encephalopathy, encephalitis, epilepsy, transverse myelitis, multiple sclerosis, hypersensitivity reactions, idiopathic thrombocytopenic purpura, diabetes, arthritis, hemolytic anemia, collagen-vascular disease) through 6months after vaccination...
December 14, 2017: Vaccine
https://www.readbyqxmd.com/read/28939272/natural-and-induced-immunization-against-ccl20-ameliorate-experimental-autoimmune-encephalitis-and-may-confer-protection-against-multiple-sclerosis
#9
Michal Abraham, Arnon Karni, Karin Mausner-Fainberg, Ido D Weiss, Amnon Peled
Th-17 type immune response that occurs in multiple sclerosis (MS) is linked to CCR6-CCL20 interaction. We confirmed the dependency on CCR6 in EAE development. Vaccination of mice with hCCL20, but not mCCL20, produced anti-murine CCL20 and ameliorated EAE. The EAE clinical score negatively correlated with anti CCL20 levels. A beneficial effect was transferred by sera from hCCL20-immunized mice. Immunized mice with cyclic peptide that include a bacterial outer membrane protein A (ompA), that share homology sequence with hCCL20 produced anti CCL20, anti ompA and anti-cyclic peptide...
September 20, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/28895088/prevalence-of-a-history-of-prior-varicella-herpes-zoster-infection-in-multiple-sclerosis
#10
Ali Manouchehrinia, Radu Tanasescu, Huner Kareem, Oltita P Jerca, Fouzia Jabeen, Rachelle Shafei, Judith Breuer, Keith Neal, William Irving, Cris S Constantinescu
Varicella zoster virus (VZV) infection has been implicated in multiple sclerosis (MS), but direct causal involvement has been disputed. Nevertheless, knowledge of VZV exposure is important, given the risk of serious complications of first exposure while undergoing immunosuppressive treatment, in particular with fingolimod. We distributed questionnaires to MS clinic patients, requesting information about history of chickenpox, sibling/household/occupational exposure, history of zoster (shingles), and disease-modifying treatment...
December 2017: Journal of Neurovirology
https://www.readbyqxmd.com/read/28799006/multiple-sclerosis-and-environmental-risk-factors-a-case-control-study-in-iran
#11
Maryam Abbasi, Seyed Massood Nabavi, Seyed Mohammad Fereshtehnejad, Nikan Zerafat Jou, Iman Ansari, Vahid Shayegannejad, Seyed Ehsan Mohammadianinejad, Mahdi Farhoudi, Abbas Noorian, Nazanin Razazian, Mahmoud Abedini, Fardin Faraji
Studies have shown an increase in the incidence of MS in Iran. The aim of our study was to evaluate the relationship between environmental exposure and MS in Iran. This case-control study was conducted on 660 MS patients and 421 controls. Many environmental factors are compared between the two groups. Our findings demonstrated that prematurity ([OR = 4.99 (95% CI 1.34-18.68), P = 0.017]), history of measles and mumps ([OR = 1.60 (95% CI 1.05-2.45), P = 0.029; OR = 1.85 (95% CI 1.22-2.78), P = 0...
November 2017: Neurological Sciences
https://www.readbyqxmd.com/read/28694135/characteristics-of-pediatric-multiple-sclerosis-the-turkish-pediatric-multiple-sclerosis-database
#12
Ünsal Yılmaz, Banu Anlar, Kıvılcım Gücüyener
OBJECTIVE: To document the clinical and paraclinical features of pediatric multiple sclerosis (MS) in Turkey. METHODS: Data of MS patients with onset before age 18 years (n = 193) were collected from 27 pediatric neurology centers throughout Turkey. Earlier-onset (<12 years) and later-onset (≥12 years) groups were compared. RESULTS: There were 123 (63.7%) girls and 70 (36.3%) boys aged 4-17 years, median 14 years at disease onset. Family history of MS was 6...
November 2017: European Journal of Paediatric Neurology: EJPN
https://www.readbyqxmd.com/read/28686222/multiple-sclerosis-immunopathology-and-treatment-update
#13
REVIEW
Narges Dargahi, Maria Katsara, Theodore Tselios, Maria-Eleni Androutsou, Maximilian de Courten, John Matsoukas, Vasso Apostolopoulos
The treatment of multiple sclerosis (MS) has changed over the last 20 years. All immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a medical challenge in MS to develop a treatment for progressive forms. The most common injectable disease-modifying therapies in RRMS include β-interferons 1a or 1b and glatiramer acetate. However, one of the major challenges of injectable disease-modifying therapies has been poor treatment adherence with approximately 50% of patients discontinuing the therapy within the first year...
July 7, 2017: Brain Sciences
https://www.readbyqxmd.com/read/28642030/cyclic-mog-35-55-ameliorates-clinical-and-neuropathological-features-of-experimental-autoimmune-encephalomyelitis
#14
Athanasios Lourbopoulos, George Deraos, Minos-Timotheos Matsoukas, Olga Touloumi, Aggeliki Giannakopoulou, Hubert Kalbacher, Nikolaos Grigoriadis, Vasso Apostolopoulos, John Matsoukas
EAE is induced to susceptible mice using linear peptides of myelin proteins of the central nervous system. Specific peptide motifs within the peptide-binding groove of the MHC peptide-complex determines the affinity of the peptide in each animal and the consequent T-cell receptor recognition and activation of the cell. Altered peptide ligand (APL) vaccination is a novel approach based on an effort to induce T-cell tolerance or alter cytokine profile from pro-inflammatory to anti-inflammatory. In the present study we synthesized the MOG35 - 55 peptide and altered its 3-dimensional conformation to make it a cyclic one (c-MOG35-55 )...
August 1, 2017: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/28603462/immune-response-to-seasonal-influenza-vaccine-in-patients-with-relapsing-remitting-multiple-sclerosis-receiving-long-term-daclizumab-beta-a-prospective-open-label-single-arm-study
#15
Lahar Mehta, Kimberly Umans, Gulden Ozen, Randy R Robinson, Jacob Elkins
BACKGROUND: For patients with relapsing-remitting multiple sclerosis (RRMS) undergoing continuous immunomodulatory therapy, understanding whether vaccinations can be performed safely and effectively is important. We tested the immune response to inactivated seasonal influenza vaccine during long-term daclizumab beta treatment. METHODS: In this prospective, open-label, single-arm extension SELECTED study, an optional vaccine substudy was performed on patients with RRMS who had already received daclizumab beta for 1 to 2 years in previous studies...
May 2017: International Journal of MS Care
https://www.readbyqxmd.com/read/28600575/altered-humoral-immunity-to-mycobacterial-antigens-in-japanese-patients-affected-by-inflammatory-demyelinating-diseases-of-the-central-nervous-system
#16
Davide Cossu, Kazumasa Yokoyama, Yuji Tomizawa, Eiichi Momotani, Nobutaka Hattori
Mycobacterium avium subsp. paratuberculosis (MAP) and Mycobacterium bovis (BCG) have been associated to several human autoimmune diseases such as multiple sclerosis (MS), but there are conflicting evidence on the issue. The objective of this study is to evaluate their role in Japanese patients affected by inflammatory demyelinating disorders of the central nervous system (IDDs). A total of 97 IDDs subjects including 51 MS and 46 neuromyelitis optica spectrum disorder (NMOSD) patients, and 34 healthy controls (HCs) were tested for the detection of IgG, IgM and IgA against mycobacterial antigens by indirect ELISA...
June 9, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28457055/short-term-efficacy-of-cbd-enriched-hemp-oil-in-girls-with-dysautonomic-syndrome-after-human-papillomavirus-vaccination
#17
Beniamino Palmieri, Carmen Laurino, Maria Vadalà
BACKGROUND: Cannabidiol (CBD)-based treatments for several diseases, including Tourette's syndrome, multiple sclerosis, epilepsy, movement disorders and glaucoma, are proving to be beneficial and the scientific clinical background of the drug is continuously evolving. OBJECTIVES: To investigate the short-term effect of CBD-enriched hemp oil for relieving symptoms and improving the life quality (QOL) in young girls with adverse drug effects (ADRs) following human papillomavirus (HPV) vaccine...
February 2017: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/28449695/intermediate-uveitis-pattern-of-etiology-complications-treatment-and-outcome-in-a-tertiary-academic-center
#18
Thomas Ness, Daniel Boehringer, Sonja Heinzelmann
BACKGROUND: Patients with intermediate uveitis (IU) represent a heterogenous group characterized by a wide spectrum of etiologies and regional differences. Aim of the study was to analyze the characteristics of patients with IU examined in an academic center in Germany. METHODS: We conducted a retrospective analysis of the clinical records of all patients with intermediate uveitis referred to the Eye Center, University of Freiburg from 2007 to 2014. Diagnosis followed the Standardization in Uveitis Nomenclature (SUN) criteria...
April 27, 2017: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/28417344/biotherapy-in-inflammatory-diseases-of-the-cns-current-knowledge-and-applications
#19
REVIEW
Nicolas Collongues, Laure Michel, Jérôme de Seze
Biotherapy represents an innovative therapeutic approach that includes immunotherapy (vaccines, apheresis, and antibodies); gene therapy; and stem cell transplants. Their development helps to cross the bridge from bench to bedside and brings new hope of a cure for severe diseases in different fields of medicine. In neurology, a growing range of applications is being developed for these medications. Valuable results are now available in the field of autoimmunity, neuro-oncology, paraneoplastic manifestations, and neurodegenerative disorders...
May 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28386258/role-of-anti-osteopontin-antibodies-in-multiple-sclerosis-and-experimental-autoimmune-encephalomyelitis
#20
Nausicaa Clemente, Cristoforo Comi, Davide Raineri, Giuseppe Cappellano, Domizia Vecchio, Elisabetta Orilieri, Casimiro L Gigliotti, Elena Boggio, Chiara Dianzani, Melissa Sorosina, Filippo Martinelli-Boneschi, Marzia Caldano, Antonio Bertolotto, Luca Ambrogio, Daniele Sblattero, Tiziana Cena, Maurizio Leone, Umberto Dianzani, Annalisa Chiocchetti
Osteopontin (OPN) is highly expressed in demyelinating lesions in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). OPN is cleaved by thrombin into N- (OPN-N) and C-terminal (OPN-C) fragments with different ligands and functions. In EAE, administering recombinant OPN induces relapses, whereas treatment with anti-OPN antibodies ameliorates the disease. Anti-OPN autoantibodies (autoAbs) are spontaneously produced during EAE but have never been detected in MS. The aim of the study was to evaluate anti-OPN autoAbs in the serum of MS patients, correlate them with disease course, and recapitulate the human findings in EAE...
2017: Frontiers in Immunology
keyword
keyword
26394
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"